Regarding pathway analysis, the presence of BET inhibitors as therapeutic for PRDM1-high stomach cancer allowed confirmation as to whether such pathways were enriched in the above coexpression signature; consequently, we uploaded this signature to Reactome [61] and found pathways including chromatin remodeling as well as epigenetic regulation were enriched in PRDM1-high stomach cancer (Figure 3). This evidence concerns the gene PRDM1 and gastric cancer.